
Silexion Therapeutics Ltd. (SLXN) Stock Ticker
SLXN right now
Market factors today
Unlock the full SLXN picture
About Silexion Therapeutics Ltd.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
SLXN stock facts
| Ticker symbol | SLXN |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $104,079 |
| CEO | Ilan Hadar |
| Employees | 14 |
| Headquarters | Jerusalem, TA, IL |
| IPO date | 2024-08-16 |
| Website | silexion.com |
What you can see for SLXN on Tickr
Live SLXN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SLXN report.
Rankings
FAQ
What is the ticker symbol for Silexion Therapeutics Ltd.?
The ticker symbol for Silexion Therapeutics Ltd. is SLXN, listed on the NASDAQ Global Market.
What is SLXN?
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates:…